Cargando…
Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans
Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pathogens and Immunity
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596135/ https://www.ncbi.nlm.nih.gov/pubmed/36320594 http://dx.doi.org/10.20411/pai.v7i2.516 |
_version_ | 1784815801320079360 |
---|---|
author | Zagaliotis, Panagiotis Michalik-Provasek, Jordyn Gill, Jason J. Walsh, Thomas J. |
author_facet | Zagaliotis, Panagiotis Michalik-Provasek, Jordyn Gill, Jason J. Walsh, Thomas J. |
author_sort | Zagaliotis, Panagiotis |
collection | PubMed |
description | Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Salmonella typhimurium. The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria. |
format | Online Article Text |
id | pubmed-9596135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Pathogens and Immunity |
record_format | MEDLINE/PubMed |
spelling | pubmed-95961352022-10-31 Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans Zagaliotis, Panagiotis Michalik-Provasek, Jordyn Gill, Jason J. Walsh, Thomas J. Pathog Immun Review Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Salmonella typhimurium. The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria. Pathogens and Immunity 2022-10-17 /pmc/articles/PMC9596135/ /pubmed/36320594 http://dx.doi.org/10.20411/pai.v7i2.516 Text en Copyright © 2022 Pathogens and Immunity https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Zagaliotis, Panagiotis Michalik-Provasek, Jordyn Gill, Jason J. Walsh, Thomas J. Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title | Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title_full | Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title_fullStr | Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title_full_unstemmed | Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title_short | Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans |
title_sort | therapeutic bacteriophages for gram-negative bacterial infections in animals and humans |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596135/ https://www.ncbi.nlm.nih.gov/pubmed/36320594 http://dx.doi.org/10.20411/pai.v7i2.516 |
work_keys_str_mv | AT zagaliotispanagiotis therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans AT michalikprovasekjordyn therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans AT gilljasonj therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans AT walshthomasj therapeuticbacteriophagesforgramnegativebacterialinfectionsinanimalsandhumans |